IONS

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

Retrieved on: 
Thursday, February 29, 2024

CARLSBAD, Calif., Feb. 29, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis as executive vice president, chief global product strategy officer, to lead all aspects of commercialization at the Company. Mr. Jenne has more than 25 years of biopharmaceutical commercial and executive leadership experience and has launched innovative medicines across a broad range of therapeutic areas including cardiovascular, neurology and allergy.

Key Points: 
  • Onaiza Cadoret-Manier, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.
  • She has built a stellar team of professionals with deep experience across all aspects of commercialization," said Brett P. Monia, Ionis' chief executive officer.
  • Mr. Jenne previously spent five years in commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020.
  • His most recent role at Ionis was as EVP & chief commercial officer.

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

Retrieved on: 
Thursday, February 8, 2024

CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults.

Key Points: 
  • CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults.
  • The FDA grants development programs Fast Track designation to facilitate the development and expedite the review of drugs that demonstrate the potential to treat serious conditions and fill an unmet medical need.
  • "CARDIO-TTRansform is the largest, most comprehensive study ever conducted in ATTR-CM patients, with results expected as early as next year."
  • WAINUA was granted Orphan Drug Designation in the U.S. and in the EU for the treatment of transthyretin-mediated amyloidosis (ATTR).

Ionis to hold fourth quarter and full year 2023 financial results webcast

Retrieved on: 
Wednesday, February 7, 2024

CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.

Key Points: 
  • Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time
    CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.
  • The live webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events .
  • A replay will be available for a limited time at the same address.

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Retrieved on: 
Tuesday, January 30, 2024

The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system.

Key Points: 
  • The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system.
  • Ionis has an option to add additional targets to the license.
  • Vect-Horus retains the rights to use its technology, for these specific targets, for all non-RNA-Targeted Medicines.
  • “This license is aligned with our strategy of using our technology to deliver drug payloads, such as RNA-targeted therapeutics, to the brain and other tissues.

Second Annual Noetic Sciences Research Prize to Recognize Groundbreaking Consciousness Research

Retrieved on: 
Thursday, January 18, 2024

NOVATO, Calif., Jan. 18, 2024 /PRNewswire-PRWeb/ -- The Institute of Noetic Sciences (IONS) is proud to announce the second annual Linda G. O'Bryant Noetic Sciences Research Prize to recognize important research in the field of consciousness. This year's prize will be awarded to the best comprehensive review comparing non-local consciousness theories. The prize explores the hypothesis that the mind is more than a neural function, and is an open challenge to the scientific position that the mind equals the brain. It carries a cash award of $100,000, as well as the opportunity for the winners to present their work to leading scientists in the field.

Key Points: 
  • NOVATO, Calif., Jan. 18, 2024 /PRNewswire-PRWeb/ -- The Institute of Noetic Sciences (IONS) is proud to announce the second annual Linda G. O'Bryant Noetic Sciences Research Prize to recognize important research in the field of consciousness.
  • This year's prize will be awarded to the best comprehensive review comparing non-local consciousness theories.
  • "We're incredibly grateful for Linda O'Bryant's visionary generosity in establishing the Noetic Sciences Research Prize in our fiftieth year," said Claudia Welss, IONS Board Chairman and Interim CEO.
  • The Linda G. O'Bryant Noetic Sciences Research Prize is an annual award open to researchers from any discipline or background.

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

Retrieved on: 
Thursday, December 21, 2023

WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.

Key Points: 
  • WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.
  • "Approval of WAINUA represents a meaningful advancement in treatment, one that gives those who are living with transthyretin-mediated amyloid polyneuropathy help managing the disease."
  • WAINUA is a ligand-conjugated antisense oligonucleotide (LICA) medicine designed to reduce the production of TTR protein at its source.
  • "There is an urgent medical need for new therapies for people living with hereditary transthyretin-mediated amyloid polyneuropathy," said Ruud Dobber, executive vice president, BioPharmaceuticals Business Unit, AstraZeneca.

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

Retrieved on: 
Monday, December 18, 2023

Ionis plans to independently bring donidalorsen to U.S. patients if approved

Key Points: 
  • Ionis plans to independently bring donidalorsen to U.S. patients if approved
    CARLSBAD, Calif., Dec. 18, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).
  • Ionis will maintain responsibility for the non-clinical and clinical development of donidalorsen, and Otsuka will be responsible for European regulatory filings and commercialization.
  • Ionis plans to independently launch donidalorsen in the U.S. if approved, as part of the company's strategy to deliver a steady flow of wholly owned medicines to patients.
  • The company plans to report Phase 3 results with donidalorsen for prophylactic treatment of HAE in the first half of 2024.

IONS Announces the Release of "Why Our Minds Wander: Understand the Science and Learn How to Focus Your Thoughts"

Retrieved on: 
Wednesday, November 15, 2023

Scheduled for release on December 19, this publication is available for pre-order from Bookshop , Target , and Amazon .

Key Points: 
  • Scheduled for release on December 19, this publication is available for pre-order from Bookshop , Target , and Amazon .
  • "Why Our Minds Wander" provides a compelling exploration of the science behind our drifting thoughts.
  • Aimed at new and intermediate seekers, this book is the perfect amalgamation of science and spirituality, offering practical advice grounded in rigorous research.
  • Daydreaming is a universal experience — our minds often wander away from the task at hand, venturing into realms unknown.

Ionis announces the appointment of Michael Yang to Board of Directors

Retrieved on: 
Thursday, December 14, 2023

CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors.

Key Points: 
  • CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors.
  • Mr. Yang's appointment expands the total number of Ionis Board members to 10.
  • "We are thrilled for Michael to join the Board as he adds deep biopharmaceutical leadership experience, particularly important as Ionis is poised to enter its next phase of growth," said Joseph Loscalzo, M.D., Ph.D., chairman of the Ionis Board of Directors.
  • "We are thrilled to have him as part of the Board and the Ionis team looks forward to working with him."

Ionis to present at upcoming investor conferences

Retrieved on: 
Friday, November 3, 2023

CARLSBAD, Calif., Nov. 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

Key Points: 
  • CARLSBAD, Calif., Nov. 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
    Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference on Tuesday, November 7, 2023
    Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023
    Piper Sandler 35th Annual Healthcare Conference 2023 on Tuesday, November 28, 2023
    BMO 2023 Growth & ESG Conference on Monday, December 4, 2023
    A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events .
  • Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.